Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. (2017)

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(17)30319-4

PubMed Identifier: 28479233

Publication URI: http://europepmc.org/abstract/MED/28479233

Type: Journal Article/Review

Volume: 18

Parent Publication: The Lancet. Oncology

Issue: 6

ISSN: 1470-2045